👉👉👉Delighted to spend some time with our trusted friend & close colleague Dr Summet Bhatia at our MDACC Cancer Network Partner Site Community Health Network CHN MD Anderson discussing new collaborations Community Health Net MD Anderson Cancer Center #CancerNetwork | #endcancer #leusm Elizabeth Rebello, MD, FASA

Congratulations to the incredible Hemepath team ARUP Laboratories UofUHeme Huntsman Cancer Institute #VEXAS #mdssm #leusm

New Research: 4-year follow-up of GAIA/CLL13:

First-line venetoclax combinations versus chemoimmunotherapy in fit patients with chronic lymphocytic #leukaemia thelancet.com/journals/lanon…

#CLL #leusm

👉👉👉Wonderful evening together celebrating the year with our amazing #TeamPemm Clinic team MDs yesterday evening at Thai Bistro! 👏 👏 👏 Hannah Goulart Akhil Jain Ani Lankford Luan Phan Hima Atluri, MD | Aditi Pemmaraju, J.D. Naveen Pemmaraju, MD | #MPNSM #leusm #BPDCN #endcancer

👉👉👉Congratulations to our wonderful colleague Dr .Hannah Goulart for being awarded the Clifton Howe Outstanding First Year Hematology/Oncology Fellow Award 🥇 for 2024!!! MD Anderson Cancer Center #MPNSM #leusm #TeamPemm | Hima Atluri, MD Sanam Loghavi, MD صنم لغوی 🔬🧬 Claire Harrison

I’m looking forward to hosting a stellar faculty with my colleagues Amer Zeidan MBBS,MHS ‏عامر زيدان Barbara Pro this summer in NYC and discuss key issues in managing patients with hematologic malignancies , hope you can join us #mmsm #leusm #lymsm #bmtsm #CARTsm

The 🔎 for optimal ven dosing continues! ASCO oral of '7+7' (7d aza/7d ven) vs. 'standard' HMA/VEN in AML:
- Similar CRc and OS
- ⬇️ 8-wk mortality w/ 7+7 (6% vs. 17%)
- ⬇️ plt transfusions

Much variation even in 'standard' HMA/VEN. What were rates of relapse?
#ASCO24 #leusm

Chronic neutrophilic #leukemia and atypical chronic myeloid leukemia: 2024 update on diagnosis, genetics, risk stratification, and management
Including key revisions to diagnostic criteria from WHO-HAEM5 and ICC systems
Open access: doi.org/10.1002/ajh.27…
#leusm #hemepath #mpnsm

Combining anti-CD3 mAbs with SMAC mimetic birinapant promotes leukemic cell death in T Cell Acute Lymphoblastic Leukemia through a pathway that depends on RIPK1. doi.org/10.1182/blood.… #leusm #hematology

Evaluating targeted therapies in older patients with TP53-mutated #AML tandfonline.com/doi/full/10.10… #leusm

It takes a village to treat a #leusm pt. I could not do this without my exceptional village Sylvester Comprehensive Cancer Center . Incredibly grateful for my team UMiami Health System Ellen Madarang 🙏🏼

VENETOCLAX-HMA AS A BRIDGE TOWARDS HSCT OR DLI IN R/R AML library.ehaweb.org/eha/2024/eha20… #EHA24 #leusm

Patient with history of myelomonocytic leukemia post treatment, below is a follow up flow cytometry analysis of his peripheral blood months later, showing an expanded population in the CD45-dim gate (aka 'blast-gate') #hemepath #PathTwitter #leusm #MedEd #MedTwitter #MedX

*Left: acute erythroid leukemia (formerly pure erythroid leukemia) nearly always shows bi-allelic loss of TP53
*Right: acute megakaryoblastic leukemia, variable genetics.
Among the most aggressive forms of AML 💀
*Both resistant to venetoclax
#hemepath #leusm

A picture (or 3) worth a thousand words
TP53-mut acute erythroid leukemia….. Sinister.. 💀
The genome looks like it was attacked by a child playing with one of those geometric rulers…
#hemepath #leusm

B-ALL now and the future … by Hagop Kantarjian,MD
40 years of progress on one slide
#leusm #hemepath

Combination therapy with novel agents for acute myeloid leukaemia: Insights into treatment of a heterogenous disease |British Journal of Haematology | Wiley Online Library onlinelibrary.wiley.com/doi/full/10.11… #AML #leusm

Management of #ALL in adults: 2024 ELN recommendations from a European expert panel ashpublications.org/blood/article/… #leusm

Advances towards genome-based acute myeloid leukemia classification: A comparative analysis of WHO-HAEM4R, WHO-HAEM5, and International Consensus Classification
Free access: doi.org/10.1002/ajh.27…
#hemepath #leusm #AML

Marta Coscia from #Torino , Italy, giving an excellent overview and treatment algorithm of #autoimmune complications in #CLL at the #GCLLSG workshop. #GCLLSG 2024 #leusm